Article
Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics.
Expert review of respiratory medicine - 1 Jan 2000
Zhang Yuda, Zeng Fanxu, Peng Shixuan, Chen Yangqian, Jiang Wenjuan, Wang Zhan, Deng Li, Huang Zhe, Qin Haoyue, Yan Huan, Zhang Xing, Zhang Lin, Yang Nong, Gong Qian, Zeng Liang, Zhang Yongchang
Abstract excerpt
INTRODUCTION: KRAS is the most frequently mutated oncogene in cancer and encodes a key signaling protein in tumors. Due to its high affinity for GTP and the lack of a large binding pocket that allosteric inhibitors can occupy, KRAS has long been considered 'non-druggable.' Finding effective treatment measures for patients with KRAS mutations is our top priority. AREAS COVERED: In this article, we will provide an...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.